Sarilumab Efficacy in 3 Phase 3 Studies
| MOBILITY | TARGET | MONARCH | ||||
|---|---|---|---|---|---|---|
| Pbo + MTX | Sarilumab 00 mg q2w + MTX | Pbo + csDMARDs | Sarilumab 200 mg q2w + csDMARDs | Adalimumab 40mg q2w | Sarilumab 200 mg q2w | |
| (N=398) | (N=399) | (N=181) | (N=184) | (N=185) | (N=184) | |
| ACR20, wk 24, % | 33.4 | 66.4* | 33.7 | 60.9* | 58.4 | 71.7† |
| ACR50, wk 24, % | 16.6 | 45.6* | 18.2 | 40.8* | 29.7 | 45.7† |
| ACR70, wk 24, % | 7.3 | 24.8* | 7.2 | 16.3* | 11.9 | 23.4† |
| HAQ-DI, mean change from baseline ± SD | ||||||
| Wk 16/12/24 | -0.3±0.6 | -0.6±0.6* | -0.3±0.5 | -0.5±0.6* | -0.4±0.6 | -0.6±0.7† |
| DAS28-CRP, mean change from baseline ± SD | ||||||
| Wk 24 | -1.6±1.4 | -3.0±1.3* | -2.0±1.2 | -3.2±1.3* | -2.1±1.2 | -2.9±1.3‡ |
| CDAI, mean change from baseline ± SD | ||||||
| Wk 24 | -20.3±15.8 | -27.9±13.2* | -23.9±12.9 | -30.4±14.5* | -25.5±12.9 | -29.7±12.7‡ |
*P<0.01 vs Pbo. †P<0.01 vs adalimumab. ‡Nominal P<0.01 vs adalimumab.